New Medical Guidelines for Pulmonary Embolism

- The annual direct medical costs of venous thromboembolism (VTE), which includes pulmonary embolism, are estimated to be between $7 billion and $10 billion in the United States. - For employers, a single pulmonary embolism case carries an average productivity loss of $7,605 in short-term disability and $48,751 in long-term disability claims. On average, an employee with PE misses 56 days for short-term disability and 364 days for long-term disability. - A key feature of the new guidelines is a clinical classification system that grades the severity of a pulmonary embolism from A (subclinical) to E (cardiopulmonary failure) to better guide treatment decisions. - The guidelines recommend multidisciplinary Pulmonary Embolism Response Teams (PERTs) for moderate to high-risk patients to improve the timeliness of care. - The recommendations favor newer direct oral anticoagulants (DOACs) over older drugs like warfarin for most patients, citing a reduced risk of major bleeding and greater ease of use. - Recent technological advancements in treatment include catheter-based therapies that use suction or mechanical means to physically remove clots from the lungs. One new technology, computer-assisted vacuum thrombectomy, has been shown to shorten hospital stays by 25-35%. - Despite advances in care, pulmonary embolism affects approximately 900,000 people in the U.S. annually, with 10% to 30% of individuals dying within one month of diagnosis.